Form 4: Armata Pharmaceuticals Executive Acquires Stock Options

David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, Inc., reports the acquisition of stock options.

Summary

• David Duane House, SVP, Finance, and PFO of Armata Pharmaceuticals, Inc., filed a Form 4.
• The form reports the acquisition of 25,000 stock options on February 5, 2025, at an exercise price of $2.04.
• These options vest 25% annually starting February 5, 2026, through 2029, contingent upon continuous service.
• Following the transaction, House beneficially owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The acquisition of stock options can be seen as a positive sign of confidence, but it's not a major event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• The vesting schedule of 25% per year over four years is a typical vesting arrangement.
• Comparing the size of the grant to similar companies and executive roles would provide further context.

Stakeholder Impact

• The stock option grant could incentivize the executive to work towards increasing shareholder value.

Key Dates